OOIR: Observatory of International Research

Papers

(The median citation count of Journal of the Peripheral Nervous System is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision	255
COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era	51
Guillain‐Barré syndrome associated with SARS‐CoV‐2 infection: A systematic review and individual participant data meta‐analysis	47
The neuropathy in hereditary transthyretin amyloidosis: A narrative review	46
Platinum accumulation in oxaliplatin‐induced peripheral neuropathy	29
Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients	28
Small and large fiber sensory polyneuropathy in type 2 diabetes: Influence of diagnostic criteria on neuropathy subtypes	26
Guillain‐Barré syndrome decreases in Singapore during the COVID‐19 pandemic	20
A longitudinal and cross‐sectional study of plasma neurofilament light chain concentration in Charcot‐Marie‐Tooth disease	20
Loss of function MPZ mutation causes milder CMT1B neuropathy	18
Recent advances in the treatment of Charcot‐Marie‐Tooth neuropathies	17
Cutaneous and muscular afferents from the foot and sensory fusion processing: Physiology and pathology in neuropathies	15
Acute and chronic inflammatory neuropathies and COVID‐19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP)	15
The Hippo pathway: Horizons for innovative treatments of peripheral nerve diseases	14
The diagnostic accuracy of the small fiber neuropathy symptoms inventory questionnaire (SFN‐SIQ) for identifying pure small fiber neuropathy	14
Report of a fulminant anti‐pan‐neurofascin‐associated neuropathy responsive to rituximab and bortezomib	14
Antecedent infections in Guillain‐Barré syndrome in endemic areas of arbovirus transmission: A multinational case‐control study	13
Antecedent infections inGuillain‐Barrésyndrome patients from south India	13
Acute small fiber neuropathy after Oxford‐AstraZeneca ChAdOx1‐S vaccination: A report of three cases and review of the literature	12
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome	12
Charcot–Marie–Toothneuropathies: Current gene therapy advances and the route toward translation	12
Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin‐related amyloidosis—A Swiss reference center experience	11
Associations of Guillain‐Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database	10
Anxiety and depression in small fiber neuropathy	10
Impact of drug formulations on kinetics and toxicity in a preclinical model of paclitaxel‐induced neuropathy	10

Long read sequencing overcomes challenges in the diagnosis of SORD neuropathy	10
Acute nitrous oxide‐induced neuropathy mimicking Guillain‐Barré syndrome	10
Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)	9
Hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE‐CIDP 1 randomized controlled tria	9
Sensory neuronopathies: A case series and literature review	9
Liver‐directed drugs for transthyretin‐mediated amyloidosis	9
A prospective study on surgical management of foot deformities in Charcot Marie tooth disease	8
Current profile of Charcot‐Marie‐Tooth disease in Africa: A systematic review	8
Proximal weakness involvement in the first Italian case of Charcot‐Marie‐Tooth 2CC harboring a novel frameshift variant in NEFH	8
Focal chronic inflammatory demyelinating polyradiculoneuropathy: Onset, course, and distinct features	8
Variants of aminoacyl‐tRNA synthetase genes in Charcot‐Marie‐Tooth disease: A Korean cohort study	8
Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy‐induced peripheral neurotoxicity: Systematic review and directions for future research	8
Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first‐line therapy	8
Charcot‐Marie‐Tooth disease: Genetic profile of patients from a large Brazilian neuromuscular reference center	7
Frequency dependent, reversible focused ultrasound suppression of evoked potentials in the reflex arc in an anesthetized animal	7
Description of a patient cohort with Hereditary Sensory Neuropathy type 1 without retinal disease Macular Telangiectasia type 2 ‐ implications for retinal screening in HSN1	7
ABSTRACT	7
Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands	7
Variations within Toll‐like receptor (TLR) and TLR signaling pathway‐related genes and their synergistic effects on the risk of Guillain‐Barré syndrome	7
Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response	6
SARM1 knockout does not rescue neuromuscular phenotypes in a Charcot‐Marie‐Tooth disease Type 1A mouse model	6
VitaminB6levels do not correlate with severity of neuropathy in chronic idiopathic axonal polyneuropathy	6
The endogenous calpain inhibitor calpastatin attenuates axon degeneration in murineGuillain‐Barrésyndrome	6
Severe distinct dysautonomia in RFC1‐related disease associated with Parkinsonism	6
Autoimmune nodo‐paranodopathies 10 years later: Clinical features, pathophysiology and treatment	6
Comorbidities, anthropometric, demographic, and lifestyle risk factors for ulnar neuropathy at the elbow: A case control study	6
Benefit of high‐dose oral riboflavin therapy in riboflavin transporter deficiency	6
Comparing neuropathy in multiple myeloma and AL amyloidosis	6
Electrodiagnostic subtyping in Guillain‐Barré syndrome: Use of criteria in practice based on a survey study in IGOS	5
Clinical and serological prognostic factors in childhoodGuillain‐Barrésyndrome: A prospective cohort study in Bangladesh	5
A new de novo SYT2 mutation presenting as distal weakness. Neuropathy or neuromuscular junction dysfunction?	5
Techniques for the standard histological and ultrastructural assessment of nerve biopsies	5
Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin‐induced peripheral neurotoxicity	5
Validation of an Artificial Intelligence driven framework to automatically detect red flag symptoms in screening for rare diseases in electronic health records: hereditary transthyretin amyloidosis po	5
An innovative phase 2 proof‐of‐concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy	5
Plasma neurofilament light chain concentrations are elevated in youth‐onset type 2 diabetes and associated with neuropathy	5
The epidemiology of Guillain‐Barré syndrome in Thailand over 13 years (2005‐2017): A nationwide population‐based retrospective cohort study	5
Targeting translation: A review of preclinical animal models in the development of treatments for chemotherapy‐induced peripheral neuropathy	5
An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy	5
Neutrophil‐lymphocyte ratio in Guillain‐Barré syndrome: A prognostic biomarker of severe disease and mechanical ventilation in Bangladesh	5
Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post‐hoc analysis of the immunoglobulin overtreatment in CIDP trial	5
2021 Peripheral Nerve Society virtual event	4
Unusual upper limb features in SORD neuropathy	4
Predicting long‐term trends in inflammatory neuropathy outcome measures using latent class modelling	4
Validation of a new hand function outcome measure in individuals with Charcot‐Marie‐Tooth disease	4
Utility of stimulus induced after discharges in the evaluation of peripheral nerve hyperexcitability: Old wine in a new bottle?	4
Axolemmal nanoruptures arising from paranodal membrane injury induce secondary axon degeneration in murine Guillain‐Barré syndrome	4
Identical late motor responses in early Guillain‐Barré syndrome: A‐waves and repeater F‐waves	4
Convergent pathological and ultrasound features in hereditary syndromic and non‐syndromic minifascicular neuropathy related to DHH	3
Clinical scoring systems for the risk of cardiovascular autonomic neuropathy in type 1 and type 2 diabetes: A simple tool	3

2020 Peripheral Nerve Society Virtual Event	3
Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study	3
Abstracts	3
Macrophages influence Schwann cell myelin autophagy after nerve injury and in a model of Charcot‐Marie‐Tooth disease	3
A robust framework for characterising diffusion metrics of the median and ulnar nerves: Exploiting state‐of‐the‐art tracking methods	3
No evidence of improvement in neuropathy after renal transplantation in patients with end stage kidney disease	3
Phase 2a randomized controlled study investigating the safety and efficacy of PDA‐002 in diabetic peripheral neuropathy	3
Toxic medications in Charcot–Marie–Tooth patients: A systematic review	3
Spontaneous activity of specific C‐nociceptor subtypes from diabetic patients and mice: Involvement of reactive dicarbonyl compounds and (sensitized) transient receptor potential channel A1	3
B‐cell and T‐cell receptor repertoire in chronic inflammatory demyelinating polyneuropathy, a prospective cohort study	3
IgM anti‐MAG^± peripheral neuropathy (IMAGiNe) study protocol: An international, observational, prospective registry of patients with IgM M‐protei	3
Quantitative sensory testing and skin biopsy findings in late‐onset ATTRv presymptomatic carriers: Relationships with predicted time of disease onset (PADO)	3
A recurrent MORC2 mutation causes Charcot‐Marie‐Tooth disease type 2Z	3
Mitofusin 1 overexpression rescues the abnormal mitochondrial dynamics caused by the Mitofusin 2 K357T mutation in vitro	2
Assessing diabetic polyneuropathy in Spanish‐speaking patients: Translation and validation of the Toronto Clinical Neuropathy Score	2
Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy	2
Chronic inflammatory demyelinating polyradiculoneuropathy: Diagnostic problems in clinical practice in Serbia	2
Nerve biopsy in acquired neuropathies	2
GJB1 variants in Charcot‐Marie‐Tooth disease X‐linked type 1 in Mali	2
Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy	2
Validation of the Italian version of the pediatric CMT quality of life outcome measure	2
Rasch‐built overall disability scale for POEMS syndrome (POEMS‐RODS)	2
Ophthalmological involvement in wild‐type transthyretin amyloidosis: A multimodal imaging study	2
Neurolymphomatosis: involvement of peripheral nervous system revealing hematologic malignancy, a report of nine cases	2
Abstracts of the Eleventh Annual Meeting of the Associazione Italiana Sistema Nervoso Periferico (ASNP)	2
The effect of tremor on disability assessment in chronic inflammatory demyelinating polyradiculoneuropathy	2
Evidence for spontaneous regulation of the humoral IgM anti‐GM1 autoimmune response by IgG antibodies in multifocal motor neuropathy patients	2
Two new mouse models of Gjb1‐associated Charcot–Marie–Tooth disease type 1X	2
Incidence of Guillain‐Barré syndrome in an Uruguayan population. A prospective cohort study	2
Peripheral neuropathy as clinical onset of monoclonal IgM/k‐related amyloidosis	2
HINT1‐related neuropathy in Greek patients with Charcot‐Marie‐Tooth disease	2
Imbalance and lower limb tremor in chronic inflammatory demyelinating polyradiculoneuropathy	2
INF2 mutations in patients with a broad phenotypic spectrum of Charcot‐Marie‐Tooth disease and focal segmental glomerulosclerosis	2
The autoimmune vulnerability of the node of Ranvier	2
	1
PNS Abstracts 2023	1
EGR2 gene‐linked hereditary neuropathies present with a bimodal age distribution at symptoms onset	1
Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis	1
Phenotypic features of RETREG1‐related hereditary sensory autonomic neuropathy	1
Disease‐specific wearable sensor algorithms for profiling activity, gait, and balance in individuals with Charcot–Marie–Tooth disease type 1A	1
Cardiovascular autonomic neuropathy in patients with type 2 diabetes with and without sensorimotor polyneuropathy	1
Development of a functional outcome measure for riboflavin transporter deficiency	1
	1
Conduction block and temporal dispersion in a SIGMAR1‐related neuropathy	1
Mutational screening of Greek patients with axonal Charcot‐Marie‐Tooth disease using targeted next‐generation sequencing: Clinical and molecular spectrum delineation	1
Imbalance and lower limb tremor in chronic inflammatory demyelinating polyradiculoneuropathy: Reply to Letter to the Editor	1
Prognostic value of neurofilament light in blood in patients with polyneuropathy: A systematic review	1
Sural nerve biopsy utility by masked assessment of individual histologic preparations	1
Inter‐rater reliability of the Rasch‐modified medical research council scoring criteria for manual muscle testing in neuromuscular diseases	1
Serum neurofilament light chain measurements following nerve trauma	1
Normal structure and pathological features in peripheral neuropathies	1
	1
Cytokines and chemokines in patients with chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: A systematic review	1
Expanding the genetic and clinical spectrum of SORD‐related peripheral neuropathy by reporting a novel variant c.210T>G and evidence of subclinical muscle involvement	1
Effectiveness of exercise therapy for individuals diagnosed with Charcot–Marie–Tooth disease: A systematic review of randomized clinical trials	1
	1
Successful autologous hematopoietic stem cell transplantation in a refractory anti‐Caspr1 antibody nodopathy	1
Somatosensory profiling of patients undergoing alcohol withdrawal: Do neuropathic pain and sensory loss represent a problem?	1
Chronic inflammatory demyelinating polyneuropathy with hypertrophic nerves	1
Validation of the parent‐proxy version of the pediatric Charcot‐Marie‐Tooth disease quality of life instrument for children aged 0–7 years	1
A severe case of neuroleukemiosis caused by B cell chronic lymphocytic leukemia, presenting as mononeuritis multiplex	1
A novel de novo variant in POLR3B gene associated with a primary axonal involvement of the largest nerve fibers	1
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision	1
PNS 2022 Abstract Supplement	1
Longitudinal follow‐up and prognostic factors in nitrous oxide‐induced neuropathy	1
Hereditary neuropathies: A pathological perspective	1
Diagnostic value of nerve conduction study in NOTCH2NLC‐related neuronal intranuclear inclusion disease	1
Serum anti‐GM2 and anti‐GalNAc‐GD1a ganglioside IgG antibodies are biomarkers for immune‐mediated polyneuropathies in cats	1
Adult‐onset Krabbe disease presenting as isolated sensorimotor demyelinating polyneuropathy: A case report	1
Validation of the parent‐proxy pediatric Charcot‐Marie‐Tooth disease quality of life outcome measure	1